Register Login

TENAYA THERAPEUTICS, INC. (TNYA)

SymbolTNYA
NameTENAYA THERAPEUTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
Address171 OYSTER POINT BOULEVARD,SUITE 500, SOUTH SAN FRANCISCO, California, 94080, United States
Telephone+1 650 - 825-6990
Fax—
Email—
Websitehttps://www.tenayatherapeutics.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001858848
Description

Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.

Additional info from NASDAQ:
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.

2026-06-29 13:00

(75% Positive) TENAYA THERAPEUTICS, INC. (TNYA) Files Form 8-K

Read more
2026-06-29 12:30

Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer

Read more
2026-06-03 11:00

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Read more
2026-06-02 20:30

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

Read more
2026-05-29 23:30

Williams R Sanders 🟢 acquired 120.0K shares (1 derivative) of Tenaya Therapeutics, Inc. (TNYA) at $0.80 Transaction Date: May 28, 2026 | Filing ID: 249135

Read more
2026-05-29 23:29

Walsh Jeffrey T. 🟢 acquired 120.0K shares (1 derivative) of Tenaya Therapeutics, Inc. (TNYA) at $0.80 Transaction Date: May 28, 2026 | Filing ID: 249132

Read more
2026-05-29 23:28

Stehman-Breen Catherine 🟢 acquired 120.0K shares (1 derivative) of Tenaya Therapeutics, Inc. (TNYA) at $0.80 Transaction Date: May 28, 2026 | Filing ID: 249131

Read more
2026-05-29 23:13

Srivastava Deepak 🟢 acquired 120.0K shares (1 derivative) of Tenaya Therapeutics, Inc. (TNYA) at $0.80 Transaction Date: May 28, 2026 | Filing ID: 249116

Read more
2026-05-29 23:09

Parschauer Karah Herdman 🟢 acquired 120.0K shares (1 derivative) of Tenaya Therapeutics, Inc. (TNYA) at $0.80 Transaction Date: May 28, 2026 | Filing ID: 249114

Read more
2026-05-29 23:08

Lee June 🟢 acquired 120.0K shares (1 derivative) of Tenaya Therapeutics, Inc. (TNYA) at $0.80 Transaction Date: May 28, 2026 | Filing ID: 249113

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT06228924 Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 … Phase1 Arrhythmogenic Right Ventricular Cardiomyopathy Recruiting 2024-03-26 2029-10-01 ClinicalTrials.gov
NCT05836259 Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerabilit… Phase1 Hypertrophic Cardiomyopathy Recruiting 2023-08-10 2032-08-01 ClinicalTrials.gov
NCT05112237 Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Car… — Cardiomyopathy Recruiting 2021-11-01 2028-06-01 ClinicalTrials.gov
Total clinical trials: 3
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
TN-401 Other Phase PHASE1 Arrhythmogenic Right Ventricular Cardiomyopathy RECRUITING NCT06228924
TN-201 Other Phase PHASE1 Hypertrophic Cardiomyopathy RECRUITING NCT05836259
Total products: 2